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Summary 
To evaluate the poss ib i l i t y  that a t r ia l  na t r i u re t i c  hormone (ANH) is 
involved in dopamine induced natr iures is  and d iures is ,  we studied 
f i ve  normal male volunteers. Each was studied on two occasions. 
During the f i r s t  two hours of each study, normal sal ine, 25 ml/hr, 
was infused. During the second two hours e i ther  normal sal ine,  25 
ml/hr, or dopamine, 4 ~g/kg/min, in normal sal ine, was infused. 
Dopamine infusion caused prominent and s ign i f i can t  nat r iures is  and 
diuresis but plasma levels of immunoreactive ANH levels did not 
change. We conclude that the ANH is not involved in dopamine 
induced natr iures is  and that dopaminergic st imulat ion is not 
responsible for  ANH secret ion. 
Dopamine infusion causes increased diuresis and nat r iures is  (1). A 
physiologic na t r iu re t i c  function of dopamine was postulated by Cuche et al (2) 
fo l lowing studies in which they analyzed ur inary catecholamines in corre lat ion 
with sodium excret ion. This nat r iures is  could be mediated by vasodi latory 
actions of dopamine (3) or other mechanisms may be involved. The recent ly  
derived na t r iu re t i c  peptides, known co l l ec t i ve l y  as a t r i a l  na t r i u re t i c  hormone 
(ANH), have potent na t r i u re t i c  ef fects in animals (4,5) and humans (6,7).  To 
evaluate a possible role of th is hormone in dopamine induced na t r iu res is ,  we 
measured the levels of immunoreactive ANH (IR-ANH) in humans during dopamine 
infusion. 
Materials and Methods 
Human subjects 
Five healthy male volunteers aged 25-37, a l l  within i(~% of ideal body 
weight, were studied. Their blood pressure was measured twice before the 
study and was found to be below 140/90. 
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Protocol of  the study 
The subjects were studied a f t e r  a 10 hour fas t  and were kept supine fo r  
the e n t i r e  4 hours of  the study wi th  except ion of assuming the up r i gh t  
pos i t i on  fo r  one vo id ing .  At 8 a.m. (0' minute of  the s tudy) ,  a f t e r  the 
subjects emptied t h e i r  bladders, a b u t t e r f l y  needle was inser ted in to  the 
vein of  each forearm. One l i n e  was used fo r  i n fus ion  and the other l i n e ,  
which was kept open by f l u s h i n g  wi th  hepar in ized sa l i ne ,  was used fo r  blood 
sampling. The to ta l  amount of heparin used did not exceed 500 un i t s .  Blood 
pressure and heart  ra te  were monitored every hour and cont inuous ECG 
moni tor ing was maintained. 
Blood samples fo r  immunoreactive ANH (IR-ANH), plasma aldosterone,  
plasma ren in  a c t i v i t y  (PRA), and plasma dopamine leve ls  were drawn at O, 
120, 180, and 240 minutes. A serum sample fo r  sodium and potassium was 
drawn at 0 minute. Two ur ine samples were co l l ec ted  at 10:00 and 12:00 
a.m., the volume was recorded and samples were analyzed fo r  sodium and 
potassium. To assure appropr ia te ur ine f low subjects drank 100 ml of tap 
water every hour. 
During the f i r s t  two hours of study (between 8:00 and 10:00 a.m.) 
25 ml/hr  of  normal sa l ine  was infused using a Harvard i n fus ion  pump. During 
the second two hours the i n fus ion  syr inge was switched to e i t he r  another 
syr inge of  normal sa l ine  or to so lu t i on  of  dopamine in normal sa l i ne .  The 
in fus ion  was cont inued at the same rate of 25 ml /hr  and the dose of dopamine 
was ca lcu la ted  so tha t  4 ~g/kg/min was infused dur ing those two hours. Each 
subject  was studied on two separate days; once using placebo (normal sa l i ne )  
i n fus ion  fo r  the e n t i r e  4 hours and once using dopamine i n fus ion  fo r  the 
l as t  two hours of the study. The protocol  was designed as a double b l i nd  
study and the code was broken only a f t e r  completion of  a l l  the i n fus ions .  
The side e f fec t s  were minimal and included nausea and one episode of 
vomit ing in one vo lun teer  and mu l t i p l e  sup raven t r i cu la r  premature beats in 
another vo lun teer .  These side e f fec t s  occured dur ing dopamine i n f us i on .  
The study was approved by the Human Studies Committee of the Un i ve r s i t y  of 
Michigan Hosp i ta l .  
Assay methods 
Serum and u r i na r y  sodium and potassium were measured using flame 
photometry. Plasma aldosterone and PRA were measured by radioimmunoassay 
(8 ,9 ) .  Dopamine concentrat ion was determined rad ioenzymat i ca l l y  by the 
method of  Peuler and Johnson ( i 0 ) .  
The radioimmunoassay fo r  IR-ANH has been described (11).  In b r i e f ,  
blood samples drawn in to  EDTA tubes were put on ice and plasma was separated 
w i t h i n  30 minutes of  sampling. Plasma was ext racted through C18 Sep Pak 
ca r t r i dges  (Waters Associates,  M i l f o r d ,  MA) and IR-ANH leve ls  were measured 
by radioimmunoassay. A l l  samples were measured in the same assay. 
In t raassay v a r i a t i o n  fo r  IR-ANH was 8.6%. 
S t a t i s t i c a l  methods 
A l l  the data are expressed as mean ± standard e r ro r .  Repeated measures 
analys is  o f  var iance (ANOVA) wi th  Newman-Keuls tes t  (NKT) was used fo r  
comparisons of  mean blood pressure, heart  ra te ,  plasma aldosterone,  PRA, 
plasma dopamine, IR-ANH, u r i na r y  volume, u r i na ry  sodium and potassium. 
Paired t t es t  was used fo r  comparisons of  serum sodium and potassium. 
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Results 
Mean blood pressure and heart rate were not s i g n i f i c a n t l y  d i f f e r e n t  during 
placebo and dopamine admin is t ra t ion (not shown). The resu l t s  of plasma 
aldosterone, PRA, ur inary  potassium, serum sodium, and serum potassium are 
shown in Table i .  No s i g n i f i c a n t  v a r i a b i l i t y  or d i f ference were found. The 
resu l t s  of u r inary  sodium, plasma dopamine and IR-ANH leve ls  are shown in 
Figure i ,  Urinary volume and sodium excret ion (both p<0.025) and plasma 
dopamine leve ls  (p<O.Ol) were increased fo l lowing dopamine in fus ion.  Plasma 
IR-ANH leve ls  were not s i g n i f i c a n t l y  a l tered by dopamine infusion (p=0.24). 
TABLE I 
Plasma Hormone Levels, Ur inary Potassium and Serum E lec t ro l y tes  During 
Infusion of Placebo and Dopamine. 
O' 120' 180' 240' 
A 1 dD~t~y_o_n e _ (~_g./d I ) 
Control 6.8 ± 0.9 
Dopamine 9.3 • 2.5 
PRA (n~Iml [hr )  
Control 2.80 * 1.32 
Dopamine 2.87 * 1.04 
Urine K (meq) 
Control 
Dopamine 
Serum Na ~ L ] ~ _  
Control 143 * i 
Dopamine 142 • i 
Serum K (meq/l) 
Control 4.3 * 0.1 
Dopamine 4.2 * 0.1 
6 . 1 1 1 . 2  
7 . 3 1 1 . 0  
2 . 9 4 ± 0 . 9 4  
3 . 6 0 ~ 1 . 3 8  
1 1 ~ 2  
9 ± 2  
5.0 • 0.9 4.9 • 1.0 
8.0 • 1.7 6.7 • 1.1 
2.60 ± 0.63 1.39 * 0.38 
2.52 4 0.44 3.47 ± 1.14 
i i ~ i  
l l l l  
Discussion 
Dopamine is one of many hormonal systems involved in the regula t ion of sa l t  
and water metabolism. Infusion of dopamine augments sodium excret ion (1) ,  and 
dopaminergic mediation may be important in the na t r i u res i s  induced by volume 
expansion. 
The exact s i t e  of dopamine action in the kidney is s t i l l  in doubt. 
Mu l t ip le  reports have shown vasod i la t ing  e f fec ts  of dopamine on the renal 
c i r c u l a t i o n  (3,12,13).  I t  has been suggested that  the sympathetic innervat ion 
of the kidney contro ls postglomerular vascular resistance (13) and that  control  
of th i s  mechanism is achieved through a balance between vasod i la t ing  e f fec ts  
of dopamine and vasocon t r i c t i ve  e f fec ts  of norepinephrine. On the other hand, 
there is evidence in cats for  a d i u re t i c  and n a t r i u r e t i c  e f f ec t  of dopamine 
which is not dependent on i t s  vascular action (14) implying a d i rec t  tubular  
e f f e c t .  Dopamine receptors were found to be present on proximal tubules (15). 
In addi t ion to d i rec t  (vascular or tubu lar )  e f fec ts  of dopamine on the 
kidney, in te rac t ions  with other renal systems of volume regu la t ion  such as 
ren in ,  k a l l i k r e i n - k i n i n  and prostaglandins as wel l  as postulated " n a t r i u r e t i c  
peptide" (16) have been suggested as addi t ional  fac tors  involved in renal 
e f fec ts  of dopamine. 
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FIG. 1 
Urinary sodium and volume, plasma dopamine and IR-ANH levels during 
placebo (open bars) and dopamine (hatched bars) administrat ion. 
Repeated measures ANOVA p <0.025 for ur inary data p <0.01 for plasma 
dopamine. 
* Newman-Keuls test  ~=0.05 compared to a l l  other groups 
o Newman-Keuls test ~=0.05 compared to corresponding 120' data 
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The recently described natriuretic peptides col lect ively known as atrial 
natriuretic hormone have potent diuretic and natriuretic effects in animals 
(4,5) and humans (6,7). Conflicting data exist in regard to a possible role 
for stimulation of D I type dopamine receptors in mediating the diuretic and 
vasodilating actions of ANH. In one report (17) the diuretic response to 
atrial extract or synthetic ANH in anaesthetized rats was completely blocked 
by the dopamine receptor antagonists haloperidol and chlorpromazine. On the 
other hand, the specific D I anatagonist SCH 23390 did not block the 
selective renal vasodilating action of ANH (18). The possibi l i ty that 
increased ANH secretion is part ia l ly  responsible for the natriuretic effects 
of dopamine has not been studied before. 
In the present study, the infusion of dopamine did not cause any changes 
in plasma levels of renin act iv i ty or aldosterone. These results are similar 
to other studies reporting the effects of intravenous dopamine in normal man 
(19,20). Intravenous dopamine infusion caused a significant diuresis and 
natriuresis when compared to placebo (normal saline) and the plasma levels of 
dopamine rose dramatically (Figure 1). IR-ANH levels did not change. These 
results exclude a role for increased secretion of atrial natriuretic hormone 
in the natriuretic and diuretic effect of dopamine. 
The dose of dopamine used in th is study was chosen af ter  prel iminary 
studies in two subjects showed that infusion of 2 ~g/kg/min was ine f fec t i ve  in 
producing nat r iures is  (data not shown). Previous studies have also shown a 
threshold dose of dopamine for nat r iures is  to be approximately 4 ~g/kg/min 
(21), This dose of dopamine has been shown to have hemodynamic ef fects  which 
are l imited to renal and mesenteric vasodi lat ion (22). 
The only known stimulatory mechanism of ANH secretion in rats and humans 
is an increase in atr ial volume. This has been shown by experiments with 
volume infusion, administration of vasopressors, water immersion, and chronic 
overload due to congestive heart fai lure (23-26). The stimulating effect of 
atrial distention cannot be blocked by vagotomy or B-blockade (27). 
Dopaminergic stimulation of atrial myocytes is another possible mechanism 
linking atrial stretch and secretion of the hormone. Based on the results of 
this study, however, a role for dopamine as a neurotransmitter involved in 
stimulation of ANH secretion appears unlikely. 
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